San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Candesant Biomedical is raising $9,133,432.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Niquette Hunt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Candesant Biomedical

Founded in 2016, the goal of the company is to develop a treatment for the 84 million Americans who suffer from excessive sweating and hyperhidrosis. We have raised funding, filed patents in the U.S. and globally, cultivated the product design as well as refined its manufacturing process, and entered pre-clinical human trials of the CDX-101 device in early 2018. Our device has proven to reduce excessive sweating in multiple areas of the body for up to six weeks – a dramatic difference from other available treatments without the often expensive or painful side effects. We anticipate the device to be commercially available in 2018 for medical professionals to use with patients.

To learn more about Candesant Biomedical, visit http://www.candesant.com/

Contact:
Niquette Hunt, President and Chief Executive Officer
413-667-9328
https://www.linkedin.com/in/niquette-hunt-480916/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved